Chung Shan Medical University   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Taichung Taiwan (1960)

Organization Overview

First Clinical Trial
2003
NCT00201396
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Cheng-Chung Wei | Chung Shan Medical University | Chung Shan Medical University Hospital | Chun Shan Medical University | David Pei-Cheng Lin | Department of Medicine, Chung Shan Medical University, Taichung, Taiwan | Department of Nutrition, Chung Shan Medical University, Taichung, Taiwan | Department of Psychology, Chung Shan Medical University, Taichung, Taiwan | School of Nutrition, Chung Shan Medical University | Yeh

Active Ingredients

Drugs in Phase 4 Trials (11)

aceclofenac (1 trial)

acetaminophen (tylenol) (1 trial)

adalimumab (humira) (1 trial)

aripiprazole (abilify) (1 trial)

budesonide (rhinocort) (1 trial)

cilostazol (pletal) (1 trial)

entecavir (baraclude) (1 trial)

etanercept (enbrel) (2 trials)

etoricoxib (Gencox) (2 trials)

lamivudine (epivir) (1 trial)

tramadol (Ultram) (1 trial)

Drugs in Phase 3 Trials (8)

cisplatin (platinol) (1 trial)

epirubicin (ellence) (1 trial)

fluorouracil (efudex) (1 trial)

jing ceih shern yuan (1 trial)

leucovorin (1 trial)

mitomycin (mutamycin) (1 trial)

naltrexone (revia) (1 trial)

ubiquinol (2 trials)

Drugs in Phase 2 Trials (19)

antroquinonol (4 trials)

astragalus membranaceus (1 trial)

celecoxib (celebrex) (1 trial)

jia-wei-xiao-yao-san, (1 trial)

letrozole (femara) (1 trial)

Liu-Wei-Die-Huang-Wan (1 trial)

meloxicam (mobic) (1 trial)

piroxicam (feldene) (1 trial)

rhodiola (1 trial)

suan tzao ren tang (1 trial)

suan-zao-ren (1 trial)

sulfasalazine (azulfidine) (1 trial)

tamoxifen (nolvadex) (1 trial)

tian wang bu xin dan (1 trial)

tonec (1 trial)

tumor necrosis factor (1 trial)

wuling san (1 trial)

ye-jiao-teng, (1 trial)

yin-chen wu ling san (1 trial)

Drugs in Phase 1 Trials (1)

misaver (1 trial)

Drugs in Other Trials (20)

aminosol (1 trial)

antrodia cinnamomea (1 trial)

astragin (1 trial)

bictegravir (Biktarvy) (1 trial)

blueberry (1 trial)

cordyceps sinensis mycelium culture extract (2 trials)

eleutherococcus senticosus (1 trial)

emtricitabine (emtriva) (1 trial)

fiber (1 trial)

hericium erinaceus mycelia (1 trial)

l-glutamine (1 trial)

losartan (cozaar) (1 trial)

mgf-4 (1 trial)

mgf-7 (1 trial)

natureheme (1 trial)

soybean (1 trial)

tenofovir alafenamide (genvoya) (1 trial)

ubiquinone (1 trial)

vigiis 101-lab (1 trial)

vitamin c (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anorexia (Phase 2)

Arthritis (Phase 4)

Arthritis, Rheumatoid (Phase 4)

Bronchopulmonary Dysplasia (Phase 4)

Cachexia (Phase 2)

Carcinoma (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Squamous Cell (Phase 2)

Cerebral Infarction (Phase 4)

Depression (Phase 4)

Depressive Disorder (Phase 4)

Depressive Disorder, Major (Phase 4)

Dermatitis (Phase 2)

Dermatitis, Atopic (Phase 2)

Diabetes Mellitus (Phase 3)

Eczema (Phase 2)

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis B (Phase 4)

Hepatitis B, Chronic (Phase 4)

Hepatitis, Chronic (Phase 4)

Hyperuricemia (Phase 2)

Infarction (Phase 1)

Inflammation (Phase 3)

Ischemia (Phase 4)

Myocardial Infarction (Phase 1)

Nasopharyngeal Carcinoma (Phase 3)

Necrosis (Phase 2)

Osteoarthritis (Phase 3)

Osteoarthritis, Knee (Phase 3)

Peripheral Arterial Disease (Phase 4)

Peripheral Vascular Diseases (Phase 4)

Respiratory Distress Syndrome (Phase 4)

Respiratory Distress Syndrome, Newborn (Phase 4)

Sjogren's Syndrome (Phase 2)

Sleep Initiation and Maintenance Disorders (Phase 2)

Spondylitis (Phase 4)

Spondylitis, Ankylosing (Phase 4)

Stroke (Phase 4)

Syndrome (Phase 2)

Uterine Cervical Neoplasms (Phase 2)

Weight Loss (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 43
  • # of Trial APIs: 59